Is BCDA or ATOS more profitable?

Atossa Genetics' return on equity of -84.91% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Atossa Genetics N/A -84.91% -72.36%

Do analysts recommend BCDA or PYRGF?

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,620.35%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, BCDA or TLPH?

BioCardia has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia $60K 174.30 -$8.23M -$0.91 N/A Talphera $30K 1,384.00 -$14.29M -$0.31 N/A

Is BCDA or TLPH more profitable?

Talphera's return on equity of -92.98% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Talphera N/A -92.98% -53.22%

Do analysts recommend BCDA or IXHL?

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,620.35%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Incannex Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or IXHL more profitable?

Incannex Healthcare's return on equity of -81.01% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Incannex Healthcare N/A -81.01% -76.11%

Do analysts recommend BCDA or MIRA?

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,620.35%. Given BioCardia's higher probable upside, equities research analysts clearly believe BioCardia is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BCDA or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -140.82% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% MIRA Pharmaceuticals N/A -140.82% -135.01%

BioCardia (BCDA) Competitors

$0.92 +0.04 (+5.08%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 0.00 (-0.11%)

As of 04:10 PM Eastern

Compare

BCDA vs. ATOS, PYRGF, TLPH, IXHL, and MIRA

Should you buy BioCardia stock or one of its competitors? MarketBeat compares BioCardia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCardia include Atossa Genetics (ATOS), PyroGenesis Canada (PYRGF), Talphera (TLPH), Incannex Healthcare (IXHL), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does BioCardia compare to Atossa Genetics?

BioCardia (NASDAQ:BCDA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Atossa Genetics had 1 more articles in the media than BioCardia. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for BioCardia. BioCardia's average media sentiment score of 1.62 beat Atossa Genetics' score of 0.94 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Very Positive
Atossa Genetics	Positive

Atossa Genetics' return on equity of -84.91% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Atossa Genetics	N/A	-84.91%	-72.36%

BioCardia has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,620.35%. Atossa Genetics has a consensus target price of $36.33, suggesting a potential upside of 649.14%. Given BioCardia's higher probable upside, analysts clearly believe BioCardia is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioCardia has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	174.30	-$8.23M	-$0.91	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Summary

BioCardia beats Atossa Genetics on 8 of the 15 factors compared between the two stocks.

How does BioCardia compare to PyroGenesis Canada?

BioCardia (NASDAQ:BCDA) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

BioCardia has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	174.30	-$8.23M	-$0.91	N/A
PyroGenesis Canada	$9.14M	4.13	-$21.12M	-$0.04	N/A

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PyroGenesis Canada had 2 more articles in the media than BioCardia. MarketBeat recorded 2 mentions for PyroGenesis Canada and 0 mentions for BioCardia. BioCardia's average media sentiment score of 1.62 beat PyroGenesis Canada's score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Very Positive
PyroGenesis Canada	Neutral

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,620.35%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioCardia has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

BioCardia has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

BioCardia beats PyroGenesis Canada on 10 of the 16 factors compared between the two stocks.

How does BioCardia compare to Talphera?

BioCardia (NASDAQ:BCDA) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Talphera's average media sentiment score of 1.89 beat BioCardia's score of 1.62 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Very Positive
Talphera	Very Positive

20.6% of BioCardia shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioCardia has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	174.30	-$8.23M	-$0.91	N/A
Talphera	$30K	1,384.00	-$14.29M	-$0.31	N/A

Talphera's return on equity of -92.98% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Talphera	N/A	-92.98%	-53.22%

BioCardia has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Talphera has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,620.35%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 275.00%. Given BioCardia's higher probable upside, equities research analysts plainly believe BioCardia is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Talphera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Talphera beats BioCardia on 7 of the 12 factors compared between the two stocks.

How does BioCardia compare to Incannex Healthcare?

BioCardia (NASDAQ:BCDA) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Incannex Healthcare's return on equity of -81.01% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Incannex Healthcare	N/A	-81.01%	-76.11%

BioCardia has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, meaning that its stock price is 600% more volatile than the broader market.

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,620.35%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioCardia has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	174.30	-$8.23M	-$0.91	N/A
Incannex Healthcare	$90K	412.83	-$46.88M	-$1.55	N/A

In the previous week, Incannex Healthcare's average media sentiment score of 1.89 beat BioCardia's score of 1.62 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Very Positive
Incannex Healthcare	Very Positive

20.6% of BioCardia shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioCardia beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

How does BioCardia compare to MIRA Pharmaceuticals?

BioCardia (NASDAQ:BCDA) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

MIRA Pharmaceuticals' return on equity of -140.82% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,620.35%. Given BioCardia's higher probable upside, equities research analysts clearly believe BioCardia is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has higher revenue and earnings than MIRA Pharmaceuticals. BioCardia is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	174.30	-$8.23M	-$0.91	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

20.6% of BioCardia shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioCardia has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

In the previous week, BioCardia's average media sentiment score of 1.62 beat MIRA Pharmaceuticals' score of 0.94 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Very Positive
MIRA Pharmaceuticals	Positive

Summary

BioCardia beats MIRA Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.46M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-1.01	18.78	23.87	24.36
Price / Sales	174.30	320.80	521.52	117.07
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	11.49	6.80	9.99	6.73
Net Income	-$8.23M	$24.09M	$3.56B	$337.03M
7 Day Performance	0.24%	-2.56%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-57.65%	48.90%	28.77%	33.98%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	3.7103 of 5 stars	$0.92 +5.1%	$25.00 +2,620.3%	-59.9%	$10.46M	$60K	N/A	40	Positive News
ATOS Atossa Genetics	2.4207 of 5 stars	$4.95 -0.2%	$36.33 +634.0%	-63.2%	$42.71M	N/A	N/A	8
PYRGF PyroGenesis Canada	N/A	$0.21 +4.6%	N/A	-53.3%	$42.32M	$9.14M	N/A	90	News Coverage Gap Up
TLPH Talphera	3.7391 of 5 stars	$0.80 -1.9%	$3.00 +275.0%	+60.7%	$42.30M	$30K	N/A	19	Positive News
IXHL Incannex Healthcare	1.1205 of 5 stars	$3.36 -4.5%	N/A	-46.3%	$42.12M	$90K	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. ATOS, PYRGF, TLPH, IXHL, and MIRA

How does BioCardia compare to Atossa Genetics?

Summary

How does BioCardia compare to PyroGenesis Canada?

Summary

How does BioCardia compare to Talphera?

Summary

How does BioCardia compare to Incannex Healthcare?

Summary

How does BioCardia compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. ATOS, PYRGF, TLPH, IXHL, and MIRA

How does BioCardia compare to Atossa Genetics?

Does the media prefer BCDA or ATOS?

Is BCDA or ATOS more profitable?

Which has more volatility & risk, BCDA or ATOS?

Do analysts recommend BCDA or ATOS?

Do institutionals and insiders hold more shares of BCDA or ATOS?

Which has better earnings and valuation, BCDA or ATOS?

Summary

How does BioCardia compare to PyroGenesis Canada?

Which has preferable valuation and earnings, BCDA or PYRGF?

Do institutionals & insiders believe in BCDA or PYRGF?

Does the media refer more to BCDA or PYRGF?

Do analysts recommend BCDA or PYRGF?

Which has more volatility and risk, BCDA or PYRGF?

Is BCDA or PYRGF more profitable?

Summary

How does BioCardia compare to Talphera?

Does the media favor BCDA or TLPH?

Do insiders & institutionals hold more shares of BCDA or TLPH?

Which has better earnings and valuation, BCDA or TLPH?

Is BCDA or TLPH more profitable?

Which has more volatility and risk, BCDA or TLPH?

Do analysts prefer BCDA or TLPH?

Summary

How does BioCardia compare to Incannex Healthcare?

Is BCDA or IXHL more profitable?

Which has more volatility and risk, BCDA or IXHL?

Do analysts recommend BCDA or IXHL?

Which has better earnings & valuation, BCDA or IXHL?

Does the media favor BCDA or IXHL?

Do insiders and institutionals hold more shares of BCDA or IXHL?

Summary

How does BioCardia compare to MIRA Pharmaceuticals?

Is BCDA or MIRA more profitable?

Do analysts recommend BCDA or MIRA?

Which has preferable valuation and earnings, BCDA or MIRA?

Do institutionals and insiders hold more shares of BCDA or MIRA?

Which has more volatility & risk, BCDA or MIRA?

Does the media refer more to BCDA or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools